N-苄氧羰基-3,4-二氢-1H-异喹啉甲酸 | 22914-95-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 中文名称: N-苄氧羰基-3,4-二氢-1H-异喹啉甲酸
• 英文名称: 2-((benzyloxy)carbonyl)-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid
• 英文别名: 2-phenylmethoxycarbonyl-3,4-dihydro-1H-isoquinoline-1-carboxylic acid
• CAS: 22914-95-0
• 化学式: C₁₈H₁₇NO₄
• 分子量: 311.337
• InChiKey: ACQYZSFXPXXIHL-UHFFFAOYSA-N

物化性质

• 沸点：
  521.6±50.0 °C(Predicted)
• 密度：
  1.308±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933499090

反应信息

• 作为反应物：
  描述：

  N-苄氧羰基-3,4-二氢-1H-异喹啉甲酸 、 2,3-二氨基苯甲酰胺 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.17h， 生成 benzyl 1-((2-amino-3-carbamoylphenyl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
  参考文献：
  名称：

  [EN] SMALL MOLECULE INHIBITORS OF PARP ACTIVITY
  [FR] INHIBITEURS À PETITE MOLÉCULE DE L'ACTIVITÉ DE PARP

  摘要：

  公开号：

  WO2011002520A3
• 作为产物：
  描述：

  1,2,3,4-四氢异喹啉-1-羧酸乙酯 在 sodium hydroxide 作用下， 以 水 为溶剂， 生成 N-苄氧羰基-3,4-二氢-1H-异喹啉甲酸
  参考文献：
  名称：

  The Dakin-West Reaction of N-Acyl-1,2,3,4-tetrahydroisoquinoline-1-carboxylic Acids Using Trifluoroacetic Anhydride: Structural Revision for the Unexpected Product

  摘要：

  The Dakin-West reaction of N-pivaloyl- and N-benzoyl-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acids (1 a-e) with trifluoroacetic anhydride yielded unexpectedly 1-(1-acyloxy-2,2,2-trifluoroethyl)-3,4-dihydroisoquinoline derivatives (3a-e) in good yields. Among of the products (3), the structure of 3 b has been confirmed by X-Ray crystallography. The carbamate derivatives (1h, i) gave 1-trifluoroacetyl-N-acyl-1,2,3,4-tetrahydroisoquinolines (4e, f), the Dakin-West reaction products, as a main product. The reaction of N-acetyl derivative (1 g) produced completely different type of the product (5).

  DOI：

  10.3987/com-97-8053

文献信息

• [EN] PYRIMIDINE-2,4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE PYRIMIDINE-2,4-DIONE, SERVANT D'ANTAGONISTES AU RECEPTEUR DE L'HORMONE DE LIBERATION DE LA GONADOTROPINE
  申请人：NEUROCRINE BIOSCIENCES INC

  公开号：WO2005007164A1

  公开（公告）日：2005-01-27

  GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure formula (I) wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, R7 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

  GnRH受体拮抗剂已被披露，可用于治疗男性和女性的各种与性激素相关的疾病。本发明的化合物具有结构式（I），其中R1a、R1b、R2a、R2b、R3、R4、R5、R6、R7和X如本文所定义，包括立体异构体、前药和其药用盐。此外，还披露了含有本发明化合物的组合物，该组合物与药用载体结合，以及涉及使用该组合物来拮抗需要此类治疗的受试者的促性腺激素释放激素的方法。
• Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
  申请人：Zhu Yun-Fei

  公开号：US20050043338A1

  公开（公告）日：2005-02-24

  GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R 1a , R 1b , R 2a , R 2b , R 3 , R 4 , R 5 , R 6 , R 7 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

  本发明披露了GnRH受体拮抗剂，可用于治疗男性和女性的各种性激素相关疾病。本发明的化合物具有以下结构：其中R1a、R1b、R2a、R2b、R3、R4、R5、R6、R7和X的定义如本文所述，包括立体异构体、前药和其药学上可接受的盐。还披露了含有本发明化合物的组合物与药学上可接受的载体，以及与其相关的方法，用于对需要拮抗促性腺激素释放激素的受体的患者进行治疗。
• SMALL MOLECULE INHIBITORS OF PARP ACTIVITY
  申请人：Panicker Bijoy

  公开号：US20120184533A1

  公开（公告）日：2012-07-19

  Compounds and pharmaceutical compositions are provided that inhibit the activity of poly ADP-ribose synthetase (PARP). Such compounds are useful in the treatment of various diseases, conditions and injuries such as stroke, myocardial infarction, ischemia-perfusion injury in various organs, traumatic brain injury, atherosclerosis, inflammatory diseases and cancer.

  提供了抑制聚腺苷酸核糖合酶（PARP）活性的化合物和制药组合物。这些化合物在治疗各种疾病、状况和损伤方面具有用处，如中风、心肌梗死、各种器官的缺血再灌注损伤、创伤性脑损伤、动脉粥样硬化、炎症性疾病和癌症。
• Small molecule inhibitors of PARP activity
  申请人：Panicker Bijoy

  公开号：US08513433B2

  公开（公告）日：2013-08-20

  Compounds and pharmaceutical compositions are provided that inhibit the activity of poly ADP-ribose synthetase (PARP). Such compounds are useful in the treatment of various diseases, conditions and injuries such as stroke, myocardial infarction, ischemia-perfusion injury in various organs, traumatic brain injury, atherosclerosis, inflammatory diseases and cancer.

  提供抑制多聚腺苷酸核糖合酶（PARP）活性的化合物和药物组合物。这些化合物在治疗各种疾病、状况和损伤方面非常有用，例如中风、心肌梗死、各种器官的缺血再灌注损伤、创伤性脑损伤、动脉粥样硬化、炎症性疾病和癌症。
• [DE] SUBSTITUIERTE TETRAHYDROISOCHINOLINE ALS MMP-INHIBITOREN, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG ALS MEDIKAMENT<br/>[EN] SUBSTITUTED TETRAHYDROISOCHINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRAGS<br/>[FR] TETRAHYDRO-ISOQUINOLEINES SUBSTITUEES, UTILISEES COMME INHIBITEURS MMP, LEUR PROCEDE DE FABRICATION ET LEUR UTILISATION COMME MEDICAMENTS
  申请人：SANOFI AVENTIS DEUTSCHLAND

  公开号：WO2006002763A3

  公开（公告）日：2006-03-16